Pfizer and Johnson & Johnson's Brewing Brawl Gets Real
Pfizer (NYSE: PFE) took direct aim at Johnson & Johnson (NYSE: JNJ) last year when it won FDA approval for Inflectra, a biosimilar to Johnson & Johnson's multi-billion dollar per year autoimmune disease drug, Remicade.
Remicade's market size made Inflectra's approval arguably the most significant approval yet for biosimilars, however, Inflectra's sales have been growing more slowly than expected, and based on a suit just filed by Pfizer, it's Johnson & Johnson that's to blame for its sluggish start.
Image source: Getty Images.
Source: Fool.com
Merck & Co. Inc. Aktie
117,44 €
-0,54 %
Die Merck & Co. Inc. Aktie in der Gunst der Community: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Ein Kursziel von 123 € für Merck & Co. Inc. impliziert ein leicht positives Wachstum gegenüber dem aktuellen Kurs von 117.44 €.
